Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

4-antibody AG

This article was originally published in Start Up

Executive Summary

4-antibody AG aims to produce fully-human, "gold standard" antibodies using its unique combination of tested technologies. The trump card: it reckons it can skirt the IP blackout zone created by pioneers around well-validated targets, thereby opening up an alterrnative route into existing, billion-dollar antibody markets.

You may also be interested in...



MSM Protein Seizes Russian Antibody Opportunity

Benefiting from pharma's ongoing love affair with antibodies-illustrated most recently in Bristol-Myers Squibb's $2 billion purchase of Medarex--Boston-based start-up MSM Protein Technologies signed two drug discovery deals in late July.

MSM Protein Seizes Russian Antibody Opportunity

Benefiting from pharma's ongoing love affair with antibodies-illustrated most recently in Bristol-Myers Squibb's $2 billion purchase of Medarex--Boston-based start-up MSM Protein Technologies signed two drug discovery deals in late July.

Finding Human Monoclonals for Infectious Disease Vaccines

A recent publication shows the ability to make high-affinity, virus-specific human monoclonal antibodies in a matter of weeks from antibody-secreting plasma cells. The research suggests, at least theoretically, that an antibody vaccine could be developed for any infectious disease, using blood from either immunized or infected individuals.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel